Brought to you by 
Onyx to buy Proteolix for $276mm plus earn-outs
01 Oct 2013
Executive Summary
Onyx Pharmaceuticals is buying privately held Proteolix (therapies for cancer and autoimmune diseases) in a deal that could be worth up to $851mm including an up-front fee and potential earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com